Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
Monoclonal antibodies targeting immune checkpoints are gaining ground in the treatment of melanoma and other cancers, and considerable effort is made to identify biomarkers predicting the efficacy of these therapies. Our retrospective study was performed on surgical tissue samples (52 lymph nodes and 34 cutaneous/subcutaneous metastases) from 30 patients with metastatic melanoma treated with ipilimumab. Using a panel of 11 antibodies against different immune cell types, intratumoral immune cell densities were determined and evaluated in relation to response to ipilimumab treatment and disease outcome. For most markers studied, median immune cell densities were at least two times higher in lymph node metastases compared to skin/subcutaneous ones; therefore, the prognostic and predictive associations of immune cell infiltration were evaluated separately in the two groups of metastases as well as in all samples as a whole. Higher prevalence of several immune cell types was seen in lymph node metastases of the responders compared to non-responders, particularly FOXP3+ cells and CD8+ T lymphocytes. In subcutaneous or cutaneous metastases, on the other hand, significant difference could be observed only in the case of CD16 and CD68. Associations of labeled cell densities with survival were also found for most cell types studied in nodal metastases, and for CD16+ and CD68+ cells in skin/s.c. metastatic cases. Our results corroborate the previous findings suggesting an association between an immunologically active tumor microenvironment and response to ipilimumab treatment, and propose new potential biomarkers for predicting treatment efficacy and disease outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Balatoni et al. (153) demonstrated that patients with melanoma who exhibited a higher frequency of Tregs in lymph node metastases responded better to ipilimumab compared with patients who had fewer Tregs (133).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [153]
In the citing paper
“decreases in Tregs in the peripheral blood and tumors of patients with metastatic melanoma treated with ICIs have been associated with ICI response and increased patient survival”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [153]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Research works printed but not linked: 1
- Balatoni T, Mohos A, Sebestyén T, Varga A, Oláh J, Lengyel Z, Emri G, Liszkay G, Ladányi A (2017) Tumor-infiltrating immune cells as potential predictive markers of response to treatment and survival in metastatic melanoma patients receiving ipilimumab. J Transl Med 15(Suppl 1):8 (O7, Abstract)
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Bai, R., Lv, Z., Xu, D., & Cui, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00209-0 · Cited by 471
Li, F., Li, C., Cai, X., Xie, Z., Zhou, L., Cheng, B., Zhong, R., Xiong, S., Li, J., Chen, Z., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101134 · Cited by 363
“[43] Balatoni T, Mohos A, Papp E, et al.”
BackgroundTumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma
Maibach, F., Sadozai, H., Seyed Jafari, S. M., Hunger, R. E., & Schenk, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02105 · Cited by 312
Fu, Q., Chen, N., Ge, C., Li, R., Li, Z., Zeng, B., Li, C., Wang, Y., Xue, Y., Song, X., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593806 · Cited by 274
Song, Y., Fu, Y., Xie, Q., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01956 · Cited by 261
“The KEYNOTE-086 study (137) used lymph nodes and cutaneous/subcutaneous metastatic surgical samples resected from patients withmetastatic melanoma treated with ipilimumab to validate the presence of tumor-infiltrating lymphocytes.”
MethodNersesian, S., Schwartz, S. L., Grantham, S. R., MacLean, L. K., Lee, S. N., Pugh-Toole, M., & Boudreau, J. E. (2021) · Translational Oncology · doi:10.1016/j.tranon.2020.100930 · Cited by 197
Tímár, J., & Ladányi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105384 · Cited by 164
Self-citationde Rodas, M. L., Nagineni, V., Ravi, A., Datar, I. J., Mino-Kenudson, M. A., Corredor, G., Barrera, C., Behlman, L., Rimm, D. L., Herbst, R. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004440 · Cited by 144
Yap suppresses T-cell function and infiltration in the tumor microenvironment
Stampouloglou, E., Cheng, N., Federico, A., Slaby, E., Monti, S., Szeto, G. L., & Varelas, X. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000591 · Cited by 104
Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer
Vihervuori, H., Autere, T.-A., Repo, H., Kurki, S. H., Kallio, L., Lintunen, M. M., Talvinen, K., & Kronqvist, P. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03036-5 · Cited by 118
Vidotto, T., Saggioro, F. P., Jamaspishvili, T., Chesca, D. L., de Albuquerque, C. G. P., dos Reis, R. B., Graham, C. H., Berman, D. M., Siemens, D. R., Squire, J. A., et al. (2019) · The Prostate · doi:10.1002/pros.23808 · Cited by 95
“A study performed with 52 melanoma lymph node metastases showed that these tumors often present high density of FoxP3+ Treg and CD8+ T cells.(49)”
de Rodas, M. L., Villalba-Esparza, M., Sanmamed, M. F., Chen, L., Rimm, D. L., & Schalper, K. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00984-x · Cited by 106
“A higher density of CD4 + TILs was also found in lymph node metastases, but not in cutaneous and/or subcutaneous metastases, from patients with a response to ipilimumab relative to those with progressive disease 82 .”
Insights into the Tumor Microenvironment—Components, Functions and Therapeutics
Baghy, K., Ladányi, A., Reszegi, A., & Kovalszky, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417536 · Cited by 90
“Accordingly, the infiltration of T lymphocytes (as well as of other immune cell types) and the expression of immune-related genes in the tumor predict response to immunotherapy [165,167].”
BackgroundSelf-citationBaysal, H., Pauw, I. D., Zaryouh, H., Peeters, M., Vermorken, J. B., Lardon, F., Waele, J. D., & Wouters, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737311 · Cited by 65
Zhan, L., Feng, H.-F., Liu, H., Guo, L., Chen, C., Yao, X.-L., & Sun, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649863 · Cited by 65
Yang, J., Lian, J. W., Chin, Y.-P. (., Wang, L., Lian, A., Murphy, G. F., & Zhou, L. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.26337 · Cited by 50
Current Trends in Cancer Immunotherapy
Filin, I. Y., Solovyeva, V. V., Kitaeva, K. V., Rutland, C. S., & Rizvanov, A. A. (2020) · Biomedicines · doi:10.3390/biomedicines8120621 · Cited by 50
Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics
Louie, A. D., Huntington, K. E., Carlsen, L., Zhou, L., & El‐Deiry, W. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.747194 · Cited by 54
“In melanoma, tumor-infiltrating immune cell subsets such as CD4+, CD8+, and FOXP3+ T cells correlate with improved treatment efficacy and disease outcome (Balatoni et al., 2018).”
BackgroundExploration of the immune cell infiltration-related gene signature in the prognosis of melanoma
Zeng, Y., Zeng, Y., Yin, H., Chen, F., Wang, Q., Yu, X., & Zhou, Y. (2021) · Aging · doi:10.18632/aging.202279 · Cited by 47
The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances
Chen, H., Yang, H., Guo, L., & Sun, Q. (2025) · MedComm · doi:10.1002/mco2.70412 · Cited by 67
Immunologic and immunogenomic aspects of tumor progression
Ladányi, A., & Tímár, J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.011 · Cited by 46
Self-citationAdvancements in Cancer Immunotherapies
Roy, R., Singh, S. K., & Misra, S. (2022) · Vaccines · doi:10.3390/vaccines11010059 · Cited by 49
Kwon, S., Velasquez, F. C., Rasmussen, J. C., Greives, M. R., Turner, K. D., Morrow, J. R., Hwu, W., Ross, R. F., Zhang, S., & Sevick-Muraca, E. M. (2019) · Theranostics · doi:10.7150/thno.35280 · Cited by 41
“Given that TILs are associated with enhanced clinical responses to ipilimumab [12], these results are consistent with improvement in response due to increased exposure to drug target in the TDLNs.”
ResultA novel prognostic biomarker LCP2 correlates with metastatic melanoma-infiltrating CD8+ T cells
Wang, Z., & Peng, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-88676-9 · Cited by 45
Szostak, B., Machaj, F., Rosik, J., & Pawlik, A. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1559297 · Cited by 38
“In the coming years, the main focus of research should be the identification of different mechanisms of toxicity, including signalling pathways, immune cells, chemokines, cytokines and growth factors [94,95].”
BackgroundImpact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors
Hou, C., Wang, Z., & Lu, X. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.08.001 · Cited by 44
Papaioannou, E. C., Sakellakis, M., Melachrinou, M., Tzoracoleftherakis, E., Kalofonos, H. P., & Kourea, E. P. (2019) · Anticancer Research · doi:10.21873/anticanres.13232 · Cited by 41
FoxP3 and IDO in Canine Melanocytic Tumors
Porcellato, I., Brachelente, C., Paolis, L. D., Menchetti, L., Silvestri, S., Sforna, M., Vichi, G., Iussich, S., & Mechelli, L. (2018) · Veterinary Pathology · doi:10.1177/0300985818808530 · Cited by 35
Lee, H., Ferguson, A. L., Quek, C. Y. J., Vergara, I. A., da Silva, I. P., Allen, R. O., Gide, T. N., Conway, J. W., Koufariotis, L. T., Hayward, N. K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2657 · Cited by 32
Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab
Shah, N., Jacob, J. M., Househ, Z., Shiner, E. K., Baird, L., & Soudy, H. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0727-5 · Cited by 30
Osella‐Abate, S., Conti, L., Annaratone, L., Senetta, R., Bertero, L., Licciardello, M., Caliendo, V., Picciotto, F., Quaglino, P., Cassoni, P., et al. (2019) · Pathology · doi:10.1016/j.pathol.2019.04.001 · Cited by 28
Gorris, M. A. J., van der Woude, L. L., Kroeze, L. I., Bol, K. F., Verrijp, K. N., Amir, A. L., Meek, J., Textor, J. C., Figdor, C. G., & de Vries, I. J. M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004329 · Cited by 35
“We believe that this is an important finding and this also validates that biopsies can be taken from any anatomical site to get reliable data on TMB, HLA-ABC expression, and lymphocyte infiltration.”
BackgroundContribution of natural killer cells in innate immunity against colorectal cancer
Ghazvinian, Z., Abdolahi, S., Tokhanbigli, S., Tarzemani, S., Piccin, A., Zali, M. R., Verdi, J., & Baghaei, K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1077053 · Cited by 24
Tian, J., & Quek, C. Y. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084243 · Cited by 25
“The increasing abundance of tumor-infiltrated CD8+ T cells has been long recognized as a strong predictor of improved ICI therapy response and prolonged PFS in melanoma [62,68–71].”
BackgroundKim, S., Kim, Y. I., Mustafa, B., Kim, M., Jeong, G., Ahn, S.-M., Lim, S., Yu, C. S., Kim, J. C., Hong, S., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0633-x · Cited by 25
Xia, F., Wu, G., Hua, J., Zhao, P., Shan, M., Wang, N., Zeng, Y., Ding, T., Zhu, H., Zhu, X., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03845-7 · Cited by 21
A B‐cell or a key player? The different roles of B‐cells and antibodies in melanoma
Rodgers, C. B., Mustard, C. J., McLean, R. T., Hutchison, S., & Pritchard, A. L. (2022) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13031 · Cited by 19
“For example, tissue cores only provide information TA B L E 1 Markers used to define B- cell subtypes in melanoma B- cell (subtype) Method used Markers used Reference B- cell Immunohistochemistry CD20+ Balatoni et al. (2018), Bosisio et al. (2016), Cabrita et al. (2020), Cipponi et al. (2012), Erdag et al. (2012), Gar…”
MethodPinard, C. J., Lagree, A., Lu, F., Klein, J., Oblak, M. L., Salgado, R., Pinto‐Cardenas, J. C., Brunetti, B., Muscatello, L. V., Sarli, G., et al. (2022) · Cancers · doi:10.3390/cancers14205008 · Cited by 23
“However, TIL infiltration in lymph node metastatic lesions is higher in ipilimumab responders than non-responders [98].”
BackgroundTissue adaptation of CD4 T lymphocytes in homeostasis and cancer
Pereira, M. V. A., Galvani, R. G. A., Gonçalves-Silva, T., de Vasconcelos, Z. F. M., & Bonomo, A. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1379376 · Cited by 21
Ziman, B., Yang, Q., Zheng, Y., Sheth, M., Nam, C., Zhao, H., Zhang, L., Hu, B., Bhowmick, N. A., Sinha, U. K., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06488-x · Cited by 17
“In fact, the abundance of intratumoral T cells is among the most reliable predictors of the effectiveness of ICB treatment (6-9).”
The therapeutic potential of targeting minimal residual disease in melanoma
Patel, R. P., Somasundram, P. M., Smith, L. K., Sheppard, K. E., & McArthur, G. A. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1197 · Cited by 23
Ladányi, A., Papp, E., Mohos, A., Balatoni, T., Liszkay, G., Oláh, J., Varga, A., Lengyel, Z., Emri, G., & Ferrone, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000209 · Cited by 17
Self-citationCheng, X., Dong, Y. Q., & Lou, F. (2021) · Cancer Management and Research · doi:10.2147/cmar.s286453 · Cited by 17
“A study conducted by Balatoni showed an association between FOXP3 cells and CD8 T lymphocytes and response to ipilimumab treatment in patients with metastatic melanoma.(28) Regarding tumor mutation burden (TMB), a recent study showing high TMB at the first follow-up seems to be associated with response and overall sur…”
ResultWang, X., Yang, Y., Wang, N., Wu, X., Xu, J., Zhou, Y., Zhao, X., & He, Z. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107437 · Cited by 19
Sheng, L., Chen, X., Wang, Q., Lyu, S., & Li, P. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109966 · Cited by 18
Matsumoto, H., Kobayashi, N., Somekawa, K., Fukuda, N., Kaneko, A., Kamimaki, C., Kubo, S., Tanaka, K., Tagami, Y., Teranishi, S., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14252 · Cited by 15
“revealed that invasion of the tumor microenvironment by immune cells, including CD4 and CD8 T cells and CD20 B cells, was positively associated with the OS after treatment.(23) One hypothesis is that monotherapy with ICIs promotes the antitumor effect of the immune cells at the site of metastasis and enhances the syst…”
BackgroundHLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab
Ladányi, A., Hegyi, B., Balatoni, T., Liszkay, G., Rohregger, R., Waldnig, C., Dudás, J., & Ferrone, S. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610297 · Cited by 16
Self-citationRasmussen, M., Durhuus, J. A., Nilbert, M. C., Andersen, O., & Therkildsen, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010329 · Cited by 16
Gut bacteria affect the tumoral immune milieu: distorting the efficacy of immunotherapy or not?
Pu, X., Chao, G., Dong, L., & Chang, P. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1739794 · Cited by 11
Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer
Čeprnja, T., Mrklić, I., Balja, M. P., Marušić, Z., Blažičević, V., Spagnoli, G. C., Juretić, A., Čapkun, V., Vuger, A. T., Vrdoljak, E., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060941 · Cited by 10
A Pan-Cancer Analysis of Clinical Prognosis and Immune Infiltration of CKS1B in Human Tumors
Jia, Y., Tian, Q., Yang, K., Liu, Y., & Liu, Y.-F. (2021) · BioMed Research International · doi:10.1155/2021/5862941 · Cited by 7
Čeprnja, T., Tomić, S., Balja, M. P., Marušić, Z., Blažičević, V., Spagnoli, G. C., Juretić, A., Čapkun, V., Vuger, A. T., Pogorelić, Z., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084513 · Cited by 9
Pietro, F. R. D., Verkhovskaia, S., Mastroeni, S., Carbone, M. L., ABENI, D. D., Rocco, C. Z. D., Samà, N., Zappalà, A., Marchetti, P., Galitiis, F. D., et al. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.09.006 · Cited by 7
PD-L1 expression and immune cells infiltration in primary tracheobronchial neoplasm
Zheng, K., Liu, Y., Ma, N., Xiong, Y., Tang, X., Zhang, Q., Luo, Z.-L., Tian, H., Hofman, P. M., Ichiki, Y., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-958 · Cited by 6
“Among several different types of immune cells, the infiltrations of CD8, FOXP3, CD16, and CD68 cells have been seen as potential biomarkers of clinical response to immunotherapy (25).”
Gâta, V. A., Paşca, A., Roman, A., Muntean, M. V., Morariu, D. Ș., Bonci, E.-A., Dina, C., & Ungureanu, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126377 · Cited by 6
“Since then, researchers have scrutinized the value of FoxP3 Tregs to determine a potential novel therapeutic target and a prognostic factor in different types of cancer with inconsistent results, especially in malignant melanoma patients [42–47].”
BackgroundThe MLL3/GRHL2 complex regulates malignant transformation and anti-tumor immunity in squamous cancer
Nam, C., Huang, G., Zheng, Y., Zhao, H., Pan, Y., Hu, B., Wenger, T. A., Van, H. T., Xu, L., Li, E., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20240758 · Cited by 9
“For example, one of the earlier studies revealed that the response of ICB therapy was directly related to the degree of intratumoral CD8 + T cells (Balatoni et al., 2018), a finding later reproduced across many different cancer types (Zheng et al., 2021; Tumeh et al., 2014).”
Martínez-Vila, C., González‐Navarro, E. A., Teixidó, C., Martin, R., Aya, F., Juan, M., & Arance, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179506 · Cited by 5
“The study examined immune subsets in lymph node tissue samples, as well as metastases located on the surface and beneath the skin [74].”
BackgroundBrugués, A., Roccuzzo, G., García‐Herrera, A., Alós, L., Malvehy, J., Puig, S., Senetta, R., Ribero, S., & Carrera, C. (2025) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2025.01.011 · Cited by 4
Metastatic perioral melanoma in a wild mountain gorilla (Gorilla beringei beringei)
Syaluha, E. K., Zimmerman, D. M., Ramer, J. C., Gilardi, K. V. K., Kabuyaya, M., Cranfield, M. R., Kent, M. S., Corner, S. M., Yeh, N. S., & Lowenstine, L. (2021) · Journal of Medical Primatology · doi:10.1111/jmp.12521 · Cited by 4
Cheng, Z., Zeng, T., Yang, G., Liu, D., Zheng, Z., & Yuan, Z. (2023) · Liver Cancer · doi:10.1159/000530273 · Cited by 5
de Wolf, A. C. M. T., Herberts, C. A., & Hoefnagel, M. H. N. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00091 · Cited by 4
Hegyi, B., Csikó, K. G., Balatoni, T., Fröhlich, G., Bőcs, K., Tóth, E., Mohos, A., Neumark, A. R., Menyhárt, C. D., Ferrone, S., et al. (2024) · Biomolecules · doi:10.3390/biom14121609 · Cited by 2
“…and infiltration by several immune cell types (e.g., CD4 + and CD8 + T lymphocytes, regulatory T cells, B lymphocytes, NK cells, CD68 + macrophages, PD-1 + and CD134 + lymphocytes) in predicting responses to treatment and/or the survival of melanoma patients receiving ipilimumab therapy [25,26].”
InfluentialSelf-citationPredictive biomarkers of inhibitors immune checkpoints therapy in malignant tumors
Kiselevsky, M. V., Самойленко, И. В., Жаркова, О. В., Ziganshina, N. V., Petkevich, A., Ситдикова, С. М., Suleymanova, A. M., Sagoyan, G. B., Михайловна, Е. М., Киргизов, К. И., et al. (2021) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2021-8-2-73-83 · Cited by 4
Tabakov, D., Maznina, A. A., Astakhova, E. A., Egorova, A. E., Захарова, Е. Н., Glushkova, O. V., Petriaikina, E. S., Svetlichnyy, D. V., Krupinova, J. A., Bogdanov, V. P., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1658970 · Cited by 3
Vaňková, L., Polívka, J., Křížková, V., Vokurka, S., Fiala, O., Holubová, M., Pivovarčíková, K., Třešková, I., Knížková, T., Říčař, J., et al. (2025) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2025.105016 · Cited by 2
Zhu, M., Li, X., Ge, Y., Nie, J. J., & Li, X. (2019) · IEEE International Conference on Big Data Computing Service and Applications (BigDataService) · doi:10.1109/bigdataservice.2019.00053 · Cited by 2
“Tumor infiltrating immune/leukocytes have been reported to be prognostic markers for the outcomes of various treatment strategies of different cancers [11-18].”
BackgroundCastello, A., & Lopci, E. (2021) · Springer eBooks · doi:10.1007/978-3-030-68858-5_8
Biomarkers predicting the effect of immunotherapy: what you need to know in practice?
Konstantinova, A. M. (2022) · Practical oncology · doi:10.31917/2302081 · Cited by 1
Brugués, A., Roccuzzo, G., García‐Herrera, A., Alós, L., Malvehy, J., Puig, S., Senetta, R., Ribero, S., & Carrera, C. (2025) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2025.07.018
Ladányi, A., Fröhlich, G., Hegyi, B., Horváth, P., & Balatoni, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1886388
Self-citation
Metadata
- Authors
- Balatoni, T., Mohos, A., Papp, E., Sebestyén, T., Liszkay, G., Oláh, J., Varga, A., Lengyel, Z., Emri, G., Gaudi, I., & Ladányi, A.
- Affiliations
- National Institute of Oncology (HU)
- Semmelweis University (HU)
- Szent János Kórház (HU)
- University of Szeged (HU)
- University of Pecs (HU)
- University of Debrecen (HU)
- Országos Korányi Tbc és Pulmonológiai Intézet (HU)
- Corresponding author
- Ladányi, Andrea
- ORCID
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2017-10-07
- Volume
- 67
- Issue
- 1
- Pages
- 141-151
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11028067
- OpenAlex
- W2761875085
- Cited by
- 76
- References
- 34
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 7 · 2023: 7 · 2022: 10 · 2021: 18 · 2020: 13 · 2019: 9 · 2018: 3 · 2017: 1
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion)
- Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- Funders
- National Research, Development and Innovation Office (K105132, K116295)
- European Union (GINOP_2.3.2-15-2016-00020)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- metastatic melanoma, ipilimumab, tumor-infiltrating immune cells, predictive biomarkers, prognostic factors, immune checkpoint inhibitors, Foxp3+ regulatory T cells, CD8+ T cells, CD16+ natural killer cells, CD68+ macrophages, lymph node metastasis, tumor microenvironment, treatment response, survival
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Adult, Aged, Female, Humans, Lymphatic Metastasis, Male, Melanoma, Middle Aged, Retrospective Studies, Biomarkers, Lymphocytes, Tumor-Infiltrating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.